Loss of exclusivityMay 2035latest FDA-listed patent expiry
CompanyVIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
Drug detail
Brand name
VELPHORO
Active ingredient
FERRIC OXYHYDROXIDE
Strength
EQ 500MG IRON
Dosage form
TABLET, CHEWABLE
Route
ORAL
Modality
Small molecule
FDA approval
November 2013
Marketing status
RX
Listed patents
Patent
Expires
Type
11234938*PED
May 2035
—
11446252*PED
May 2035
—
10624855*PED
May 2035
—
10624855
November 2034
product
11446252
November 2034
product
11234938
November 2034
product
9561251*PED
July 2030
—
9561251
January 2030
product
10695367*PED
May 2029
—
11013762*PED
May 2029
—
10925896*PED
May 2029
—
10925897*PED
May 2029
—
10933090*PED
May 2029
—
10682376*PED
May 2029
—
11013761*PED
May 2029
—
10925896
November 2028
product
10682376
November 2028
product
11013761
November 2028
product
10925897
November 2028
product
11013762
November 2028
product
10933090
November 2028
product
10695367
November 2028
product
Regulatory exclusivity
Code
Expires
PED
January 2028
NPP
July 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
VELPHORO patent cliff — loss of exclusivity May 2035 | CliffBio